Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731664 | 0.89 | ALDH1A1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL14432755 | 0.86 | DGKA (0.46) | ALDH1A1CES2CES1TSHR | |
| SCHEMBL7887094 | 0.85 | DGKA (0.48) | ALDH1A1CES2CES1TSHR | |
| SCHEMBL17204502 | 0.85 | DGKA (0.48) | ALDH1A1CES2CES1TSHR | |
| SCHEMBL7262371 | 0.85 | DGKA (0.48) | ALDH1A1CES2CES1TSHR | |
| SCHEMBL10640242 | 0.82 | ALDH1A1 (0.94) | ALDH1A1CES2CES1FFAR3HDAC3 | |
| SCHEMBL5968591 | 0.81 | EGLN1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL4098529 | 0.80 | MGAM (0.41) | ALDH1A1TSHR | |
| SCHEMBL8909532 | 0.80 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL11879992 | 0.80 | ALDH1A1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335454-A1 | URATE OXIDASE PREPARATION AND USE THEREOF | Hangzhou Grand Biologic Pharmaceutical Inc. (CN) | 2024-03-13 | — | — | EP | claimed |
| US-20230346959-A1 | URATE OXIDASE PREPARATION AND USE THEREOF | HANGZHOU GRAND BIOLOGIC PHARMACEUTICAL INC. (CN) | 2023-11-02 | — | — | US | claimed |
| US-20230346896-A1 | METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE | HANGZHOU GRAND BIOLOGIC PHARMACEUTICAL INC. (CN) | 2023-11-02 | — | — | US | claimed |
| EP-4241841-A1 | METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE | Hangzhou Grand Biologic Pharmaceutical Inc. (CN) | 2023-09-13 | — | — | EP | claimed |
| US-20150224207-A1 | THIOL-SELECTIVE WATER-SOLUBLE POLYMER DERIVATIVES | NEKTAR THERAPEUTICS | 2015-08-13 | — | — | US | claimed |
| US-7910661-B2 | Thiol-selective water-soluble polymer derivatives | NEKTAR THERAPEUTICS (US) | 2011-03-22 | — | — | US | claimed |
| JP-4490413-B2 | — | — | 2010-06-23 | — | — | JP | claimed |
| JP-2006517600-A | — | — | 2006-07-27 | — | — | JP | claimed |
| EP-1581582-A1 | THIOL-SELECTIVE WATER-SOLUBLE POLMER DERIVATIVES | Nektar Therapeutics Al, Corporation (US) | 2005-10-05 | — | — | EP | claimed |
| US-20050014903-A1 | Polymer coupling to thiol group containing compound; activation | NEKTAR THERAPEUTICS | 2005-01-20 | — | — | US | claimed |
| WO-2004063250-A1 | THIOL-SELECTIVE WATER-SOLUBLE POLMER DERIVATIVES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2004-07-29 | — | — | WO | claimed |
| US-11993630-B2 | Method for purifying PEGylated erythropoietin | Hoffmann-La Roche Inc (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4335454-A1 | URATE OXIDASE PREPARATION AND USE THEREOF | Hangzhou Grand Biologic Pharmaceutical Inc. (CN) | 2024-03-13 | — | — | EP | disclosed |
| US-20230346896-A1 | METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE | HANGZHOU GRAND BIOLOGIC PHARMACEUTICAL INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230346959-A1 | URATE OXIDASE PREPARATION AND USE THEREOF | HANGZHOU GRAND BIOLOGIC PHARMACEUTICAL INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20050014903-A1 | Polymer coupling to thiol group containing compound; activation | NEKTAR THERAPEUTICS | 2005-01-20 | — | — | US | disclosed |
| WO-2004063250-A1 | THIOL-SELECTIVE WATER-SOLUBLE POLMER DERIVATIVES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-0144422-A1 | STABILIZATION OF NEUTROPHILS AND PLATELETS | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1985-06-19 | — | — | EP | disclosed |
| WO-1984004870-A1 | STABILIZATION OF NEUTROPHILS AND PLATELETS | NEW ENGLAND MEDICAL CENTER INC (US) | 1984-12-20 | — | — | WO | disclosed |
| US-4471051-A | REACTING WITH A CLEAVABLE CROSSLINKING AGENT FOR STORAGE; REGENERATION; KITS; LEUKOCYTES | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1984-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224207-A1 | THIOL-SELECTIVE WATER-SOLUBLE POLYMER DERIVATIVES | TST, PWWP2B, PDIA6 | ALDH1A1 2893/4885CES2 3816/4885CES1 4099/4885 |
| US-11993630-B2 | Method for purifying PEGylated erythropoietin | EPOR, PDGFRA, TFRC | ALDH1A1 4372/4885CES2 3788/4885CES1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.